Full Year
RMD — ANNUAL 2026 Financial Report Analysis
ResMed's FY2026 (year to June 30) revenue rose 10% to $5.65B and gross margin widened to 61.1% on manufacturing and procurement savings, but a $42M Astral ventilator recall charge and a tax rate up to 20.6% held GAAP EPS growth to 9.7% ($10.43).